Alumis Announces $175M Common Stock Offering to Fund NDA & Operations Following Positive Phase 3 Results

summarizeSummary

Alumis Inc. is conducting a $175 million common stock offering, with an option for an additional $26.25 million, to fund the NDA filing and launch preparations for envudeucitinib in plaque psoriasis, clinical development, and general corporate purposes. This capital raise is critical given the company's "going concern" warning, but is enabled by recent positive Phase 3 trial results for its lead candidate.

check_boxKey Events

• Common Stock Offering Announced

  Alumis is offering $175 million of common stock, with an option for underwriters to purchase an additional $26.25 million, potentially raising up to $201.25 million.

• Addresses Going Concern Warning

  The capital raise is crucial as the company has explicitly stated a "going concern" warning, indicating existing cash is insufficient for the next 12 months.

• Follows Positive Phase 3 Results

  The financing immediately follows the announcement of positive topline results from Phase 3 ONWARD1 and ONWARD2 trials for envudeucitinib in moderate-to-severe plaque psoriasis, meeting all primary and secondary endpoints.

• Funding for NDA and Pipeline

  Proceeds will fund the New Drug Application (NDA) regulatory filing and launch preparations for envudeucitinib in PsO, clinical development of other pipeline programs, and general corporate purposes.

auto_awesomeAnalysis

This substantial capital raise, representing approximately 10-12% of Alumis's current market capitalization, is a critical financing event for the company. The offering is necessary to address a "going concern" warning, as existing cash is insufficient for the next 12 months. However, the timing is strategic, following the announcement of positive topline Phase 3 results for envudeucitinib in moderate-to-severe plaque psoriasis, which met all primary and secondary endpoints with high statistical significance. This successful trial significantly de-risks the lead candidate and provides a strong basis for the capital raise, enabling the company to fund the New Drug Application (NDA) submission in the second half of 2026 and prepare for a potential launch. While the offering is dilutive, it provides essential funding to advance the company's pipeline and capitalize on its clinical success, mitigating immediate financial risks.